Macular oedema is a leading cause of vision loss in patients with radiation retinopathy. In an effort to find an effective treatment for this vision threatening complication, 12 eyes (eight patients) were treated with photocoagulation for clinically significant radiation macular oedema (CSRMO) defined as central macular thickening, exudates threatening the macular centre, or one disc area of thickening in the macula. Median visual acuity improved from 20/100 preoperatively to 20/90 at the initial postoperative examination (mean follow up 5 months) and to 20/75 at the final postoperative examination (mean follow up 39 months). At the final postoperative examination, visual acuity had improved in eight (67%) eyes and six (50°/0) eyes had complete resolution of the CSRMO; two (17%) other eyes had improved anatomically in that fewer CSRMO criteria were present. These results suggest that macular photocoagulation is effective in decreasing macular oedema and improving vision in eyes with CSRMO. (Br_r Ophthalmol 1995; 79: (1) (centre) retinal thickening at or within 500 ,um of the centre of the macula;
Radiation is being used with increasing frequency to treat not only malignant but also benign orbital, ocular, head, and neck tumours. Despite improved localisation and increased precision of dosage calculation and delivery, normal surrounding tissue continues to be adversely affected. Particularly sensitive to harmful effects of radiation are the capillaries supplying the macula; the resultant radiation macular oedema is a frequent cause of vision loss in patients after radiation treatment. ' 2 If the Collaborative Ocular Melanoma Study3 results show that radiation treatment is preferable to enucleation, it will be even more imperative to find effective treatment for secondary complications of the radiation treatment, especially radiation macular oedema.
Short term results of one such treatment, photocoagulation, for clinically significant radiation macular oedema (CSRMO) in four patients (five eyes) have previously been published. 4 We now report longer follow up findings in these patients plus the visual acuity and anatomical results of treatment in four additional patients (seven eyes).
Patients and methods Eight patients, four with bilateral involvement or a total of 12 eyes, were enrolled and gave informed consent for macular photocoagulation treatment. To be eligible, affected patients had to have a history of radiation treatment around the eyes or head as well as clinical findings consistent with radiation retinopathy (microaneurysms, telangiectasia, and/or nerve fibre layer infarcts) plus radiation macular oedema with one or more criteria for being clinically significant as defined by the Early Treatment Diabetic Retinopathy Study
Research Group.5 These criteria include:
(1) (centre) retinal thickening at or within 500 ,um of the centre of the macula;
(2) (exudates) hard exudates within 500 ,um of the centre of the macula, if associated with adjacent retinal thickening; or (3) (zone) a zone or zones of retinal thiclkening one disc area or larger, any part of which is within one disc diameter of the centre of the macula.
Eyes with macular oedema which was not clinically significant (retinal thickening or appreciable hard exudates within one disc diameter of the centre of the macula)6 were not eligible for treatment. None of our patients' retinopathy was suggestive of a branch vein occlusion (sectoral distribution) or central retinal vein occlusion (venous dilatation). One patient had adult onset diabetes mellitus but the retinopathy did not occur until 11 months after radioactive plaque treatment, and this patient's opposite macula was normal. Examination techniques used to detect radiation retinopathy, macular oedema, and CSRMO included ophthalmoscopy (direct and indirect), contact lens fundus biomicroscopy, and stereoscopic colour fundus photographs.
Snellen visual acuity was measured and recorded by independent examiners at the preoperative and postoperative examinations. For eyes with visual acuity less than 20/400, acuity was recorded as counting fingers or hand movements. For visual acuity analyses, counting fingers and hand movements were arbitrarily converted to 20/800 and 20/1600, respectively. Preoperative stereoscopic colour fundus photographs and fluorescein angiograms were obtained for all 12 postoperative examination), and the final postoperative examination. Because of sample size, it is not likely that any comparisons are statistically significant; therefore, we limit ourselves to descriptive statistics.
The photocoagulation treatment techniques used in our patients are the same as those recommended for treatment of clinically significant diabetic macular oedema.5 7 Fluorescein angiograms were used to identify leaking microaneurysms and areas of capillary non-perfusion and diffuse leakage judged to be responsible for the CSRMO. Fifty and 100 ,m green and blue green laser burns were used to turn the microaneurysms dark red or white; the same size burns of moderate intensity and spaced one burn diameter apart were used when applying a limited scatter (grid) treatment to areas of capillary non-perfusion and diffuse leakage. 
Results
Five men and three women were enrolled. Seven right eyes and five left eyes met the inclusion criteria for macular photocoagulation treatment. The four eyes in these patients which were not treated included two normal eyes of two patients with unilateral intraocular tumour, one eye with a markedly atrophic nerve and macula due to radiation damage, and one eye with very early radiation retinopathy (only occasional retinal haemorrhages and microaneurysms). The mean age of these patients at the time of radiation treatment was 35 years with a range of 6 months to 62 years. The mean age at the first treatment for CSRMO was 44 years with a range of 17 to 70 years. The indications for radiation treatment included three patients (five eyes) with Graves' ophthalmopathy,8 three patients (five eyes) with central nervous system tumour, and two patients (two eyes) with intraocular tumour. Eleven eyes were treated with external beam irradiation and one eye had local radioactive plaque treatment of a peripheral choroidal melanoma. Mean fraction size was 276 rad based on a mean total of 4971 rad given over a mean total of 18 fractions (ranges of 2000 to 10 710 rad and 1 to 33 fractions). The mean (median) latencies for the first diagnosis of radiation retinopathy, macular oedema, and CSRMO were 55 (27), 70 (34), and 87 (83) months, respectively. The range for each of these three diagnoses was 11-273, 11-273, and 11-329 months, respectively.
At the time of macular photocoagulation, all 12 eyes had thickening involving the centre of the macula, seven eyes had hard exudates associated with thickening, and 10 eyes had a disc area of thickening. The median preoperative visual acuity for these 12 eyes was 20/100 with a range of 20/40 to counting fingers. At the initial postoperative examination (mean of 5 months with range of 3-8 months after treatment), the median visual acuity was 20/90 with a range of 20/20 to counting fingers. The mean total follow up for these 12 eyes was 39 (range 6-76) months. Median visual acuity at the final postoperative examination was 20/75 with a range of 20/20 to hand motion.
During follow up, these 12 eyes had an average of one retreatment for persistent or recurrent clinical significant macular oedema. The total number of retreatments ranged from 0 to 4; eight eyes had one or no retreatment. Additional macular photocoagulation was recommended for two patients (two eyes) at the final postoperative examination.
We found that a majority of eyes (seven and eight) had better visual acuity at both the initial and final postoperative examinations, respectively (Fig 1) . Four eyes had at least halving of the visual angle at the initial postoperative examination and seven eyes had improved this amount at the final postoperative examination. One and three eyes at the initial and final postoperative examinations, respectively, had worse vision. Four eyes had the same vision at the initial postoperative examination and one eye had the same vision at the final examination. The mean total follow up for the eyes (Table 3) .
The hallmark clinical finding of radiation retinopathy is the widespread capillary nonperfusion demonstrated with fluorescein angiography. The resultant macular ischaemia (defined as capillary dropout around the fovea) seen in all 12 of our study eyes supports present knowledge that the primary pathology in radiation retinopathy is damage to vascular endothelial cells.10 Capillary non-perfusion also occurs in diabetic retinopathy but usually not so extensively as seen in radiation retinopathy. The more extensive capillary non-perfusion in radiation retinopathy may decrease the beneficial effect of photocoagulation treatment for radiation macular oedema, but the extent of capillary non-perfusion necessary to eliminate any possible beneficial effect is not known In addition to follow up for development of high risk characteristics, eyes with radiation retinopathy need to be followed for recurrent and persistent CSRMO. Retreatment was offered to our patients if CSRMO was present at any follow up examination and microaneurysms, areas of capillary non-perfusion, or diffuse leakage were identified which could be responsible for the CSRMO. This need for follow up and retreatment, if necessary, is similar to eyes with clinically significant diabetic macular oedema.15
In addition to the visual acuity results, we believe the anatomical results also support a beneficial effect of photocoagulation for CSRMO. The anatomical improvement in eight of these 12 eyes, as judged by a decreased number of CSRMO criteria, suggests the treatment techniques used in this study were successful in decreasing the retinal oedema. Not all treated eyes, however, respond as judged by absence or decreased number of CSRMO criteria following treatment. Comparable anatomical results of macular photocoagulation in diabetic eyes are not available for comparison with our data. 
